• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

牛磺酸 - 非肌肉浸润性膀胱癌的可能指纹生物标志物:1H NMR 光谱的初步研究。

Taurine - a possible fingerprint biomarker in non-muscle invasive bladder cancer: A pilot study by 1H NMR spectroscopy.

机构信息

Centre of Biomedical Magnetic Resonance, Sanjay Gandhi Post-Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.

出版信息

Cancer Biomark. 2010;6(1):11-20. doi: 10.3233/CBM-2009-0115.

DOI:10.3233/CBM-2009-0115
PMID:20164538
Abstract

Urinary bladder cancer is a major epidemiological problem that continues to grow each year. It opens avenues for investigative research for the identification of new disease markers and diagnostic techniques. In this pilot study, utility of non-invasive (1)H NMR spectroscopy has been evaluated for probing the metabolic perturbations occurring in non-muscle invasive urinary bladder cancer. (1)H NMR spectra of urine of bladder cancer patients and controls (healthy and urinary tract infection/bladder stone) (n = 103) were acquired at 400MHz. The non-overlapping resonances of citrate, dimethylamine, phenylalanine, taurine and hippurate were first identified and then quantitated by (1)H NMR spectra, with respect to an external reference sodium-3-trimethylsilylpropionate (TSP). The concentrations of these metabolites were then statistically analyzed. The cancer patients showed significant (p < 0.05) variations in concentration of hippurate and citrate as compared with healthy controls and benign controls. The significant elevation in concentration of taurine was observed in urine of bladder cancer patients, which was below the sensitivity limit of 400MHz in control cases. However, stages Ta, T1 and carcinoma in situ (CIS) cannot be differentiated on the basis of altered metabolite indices but their composition may reflect the biochemical alterations in metabolism of cancer cells.

摘要

膀胱癌是一个日益严重的主要流行病学问题。这为寻找新的疾病标志物和诊断技术开辟了研究途径。在这项初步研究中,评估了无创(1)H NMR 光谱用于探测非肌肉浸润性膀胱癌发生的代谢紊乱的效用。在 400MHz 下采集了膀胱癌患者和对照组(健康和尿路感染/膀胱结石)(n=103)的尿液的(1)H NMR 光谱。首先通过(1)H NMR 光谱鉴定并定量了柠檬酸、二甲胺、苯丙氨酸、牛磺酸和马尿酸的非重叠共振峰,相对于外部参考物 3-三甲基硅丙酸钠(TSP)。然后对这些代谢物的浓度进行了统计学分析。与健康对照组和良性对照组相比,癌症患者的马尿酸和柠檬酸浓度有显著(p < 0.05)变化。在膀胱癌患者的尿液中观察到牛磺酸浓度显著升高,但在对照组中,其浓度低于 400MHz 的灵敏度极限。然而,基于改变的代谢物指数无法区分 Ta、T1 和原位癌(CIS),但其组成可能反映了癌细胞代谢的生化变化。

相似文献

1
Taurine - a possible fingerprint biomarker in non-muscle invasive bladder cancer: A pilot study by 1H NMR spectroscopy.牛磺酸 - 非肌肉浸润性膀胱癌的可能指纹生物标志物:1H NMR 光谱的初步研究。
Cancer Biomark. 2010;6(1):11-20. doi: 10.3233/CBM-2009-0115.
2
Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer.Hyal1 和 survivin RNA 的表达可作为膀胱癌的诊断分子标志物。
J Urol. 2010 Feb;183(2):493-8. doi: 10.1016/j.juro.2009.10.024. Epub 2009 Dec 14.
3
[The diagnostic value of microsatellite LOH analysis and the prognostic relevance of angiogenic gene expression in urinary bladder cancer].[微卫星杂合性缺失分析在膀胱癌中的诊断价值及血管生成基因表达的预后相关性]
Magy Onkol. 2009 Dec;53(4):385-9. doi: 10.1556/MOnkol.53.2009.4.8.
4
Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.核基质蛋白、纤连蛋白、膀胱癌抗原及晨尿细胞学检查在膀胱肿瘤检测中的比较评估
J Urol. 2002 Aug;168(2):465-9.
5
The clinical value of CYFRA21-1 in bladder cancer patients: Egyptian experience.细胞角蛋白19片段21-1(CYFRA21-1)在膀胱癌患者中的临床价值:埃及的经验。
Anticancer Res. 1999 Jul-Aug;19(4A):2603-8.
6
[Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].[尿BTA-TRAK在浅表性移行细胞膀胱癌随访中的应用]
Arch Esp Urol. 2002 Jan-Feb;55(1):41-9.
7
Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.评估尿CYFRA 21-1用于检测原发性和复发性膀胱癌的情况。
Cancer. 2002 Jun 1;94(11):2914-22. doi: 10.1002/cncr.10565.
8
Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer.使用联合尿核基质蛋白-22、单核细胞趋化蛋白-1和尿细胞间黏附分子-1检测膀胱癌的神经网络
J Urol. 2003 Mar;169(3):917-20. doi: 10.1097/01.ju.0000051322.60266.06.
9
Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.评估尿肿瘤相关胰蛋白酶抑制剂、细胞角蛋白19片段(CYFRA 21-1)及膀胱癌抗原用于检测高级别膀胱癌的情况。
Urology. 2008 Nov;72(5):1159-63. doi: 10.1016/j.urology.2008.04.009. Epub 2008 Jun 2.
10
Molecular alterations associated with bladder cancer initiation and progression.与膀胱癌起始和进展相关的分子改变。
Scand J Urol Nephrol Suppl. 2008 Sep(218):154-65. doi: 10.1080/03008880802291915.

引用本文的文献

1
Interplay of serum taurine, S-adenosylmethionine, and cysteine levels in cancer risk: a prospective study.血清牛磺酸、S-腺苷甲硫氨酸和半胱氨酸水平在癌症风险中的相互作用:一项前瞻性研究。
Front Pharmacol. 2024 Dec 18;15:1507125. doi: 10.3389/fphar.2024.1507125. eCollection 2024.
2
Mesenchymal stem cells in tumor microenvironment: drivers of bladder cancer progression through mitochondrial dynamics and energy production.肿瘤微环境中的间充质干细胞:通过线粒体动力学和能量产生驱动膀胱癌进展。
Cell Death Dis. 2024 Sep 20;15(9):688. doi: 10.1038/s41419-024-07068-9.
3
Metabolomics for the diagnosis of bladder cancer: A systematic review.
代谢组学在膀胱癌诊断中的应用:一项系统综述。
Asian J Urol. 2024 Apr;11(2):221-241. doi: 10.1016/j.ajur.2022.11.005. Epub 2023 Sep 12.
4
Evaluating changes in firefighter urinary metabolomes after structural fires: an untargeted, high resolution approach.评估结构火灾后消防员尿液代谢组的变化:一种非靶向、高分辨率的方法。
Sci Rep. 2023 Nov 27;13(1):20872. doi: 10.1038/s41598-023-47799-x.
5
Urinary Biomarkers and Point-of-Care Urinalysis Devices for Early Diagnosis and Management of Disease: A Review.用于疾病早期诊断和管理的尿液生物标志物及即时检验尿液分析设备:综述
Biomedicines. 2023 Mar 29;11(4):1051. doi: 10.3390/biomedicines11041051.
6
LC-MS metabolomics of urine reveals distinct profiles for non-muscle-invasive and muscle-invasive bladder cancer.尿液 LC-MS 代谢组学揭示了非肌肉浸润性和肌肉浸润性膀胱癌的不同特征。
World J Urol. 2022 Oct;40(10):2387-2398. doi: 10.1007/s00345-022-04136-7. Epub 2022 Sep 4.
7
Metabolic Profiling of Bladder Cancer Patients' Serum Reveals Their Sensitivity to Neoadjuvant Chemotherapy.膀胱癌患者血清的代谢谱分析揭示了他们对新辅助化疗的敏感性。
Metabolites. 2022 Jun 17;12(6):558. doi: 10.3390/metabo12060558.
8
Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer.代谢组学方法在膀胱癌生物标志物和相关通路检测及鉴定中的应用。
Int J Mol Sci. 2022 Apr 10;23(8):4173. doi: 10.3390/ijms23084173.
9
Guide to Metabolomics Analysis: A Bioinformatics Workflow.代谢组学分析指南:一种生物信息学工作流程。
Metabolites. 2022 Apr 15;12(4):357. doi: 10.3390/metabo12040357.
10
Metabolomics in endometriosis: challenges and perspectives for future studies.子宫内膜异位症的代谢组学:未来研究的挑战与展望。
Reprod Fertil. 2021 May 6;2(2):R35-R50. doi: 10.1530/RAF-20-0047. eCollection 2021 Apr.